TPST

Announcements

Nothing here yet

Daily updates

• Tempest Therapeutics entered an exclusive option agreement with Senlang for in vivo CAR-T technologySep 16, 2026
• Tempest Therapeutics secured an exclusive option for Senlang's CD7 lentiviral vector and in vivo CAR-T technologySep 16, 2026

FDA designations

Nothing here yet

News

• Tempest secured an exclusive option to license a clinical-stage CD7-targeted lentiviral in vivo CAR-T platformSep 16, 2026
• Tempest enters a development collaboration with Senlang Biotechnology for TPST-4003, a next-generation CD7-targeted in vivo CAR-T therapyJul 21, 2026
• Tempest announced a key manufacturing milestone for TPST-2003 dual-targeting CD19/BCMA CAR-T therapyApr 22, 2026
• Tempest reports interim results from the ongoing REDEEM-1 trial of TPST-2003 and prepares for a potential U.S. registrational study in 2026Feb 25, 2026
• Tempest receives clearance to start pivotal trial of Amezalpat combination therapy for first-line HCC in ChinaJun 30, 2025